Working to Eradicate Gynecologic Cancers

Keaven Anderson, PhD

Executive Director
Merck & Co., Inc.
One Merck Drive
Whitehouse Station, NJ
USA 08889

Papers:
448 - Poster Session B CA-125 as a response marker for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: the PRECEDENT trial 450 - Poster Session B Model prediction of mean PFS and OS time from a phase II trial comparing vintafolide plus pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer patients with 100% folate receptor–positive target